Nieuws

Recent

Selecteer een categorie:

Vul een zoekterm in.

22/07/11
1ST HALF-YEAR 2011: Sales up 10%, solid performance in a disrupted environment and upward revision of full-year targets

[meer...]

30/05/11
With the inauguration of its new site, Stallergenes continues its development and creates value in France

[meer...]

10/05/11
Stallergenes opent nieuwe productiefaciliteit voor graspollen

[meer...]

19/04/11
Onder de tong tablet wordt nieuwe standaard behandelingsvorm

[meer...]

13/01/11
Turnover in 2010 : a continued growth in Q4

[meer...]

04/01/11
100 Years after its Discovery, Allergen Immunotherapy enters a new Era

[meer...]

01/08/10
Anti-allergiemiddel Oralair is de eerste kortdurende sublinguale immunotherapie

[meer...]

01/07/10
Evidence-based Oralair klaar voor Nederlandse introductie

[meer...]

28/06/10
Persistent efficacy demonstrated after a year on Actair® followed by a 2nd treatment-free year

[meer...]

21/06/10
Staloral® Mites 300 Clinical study in China

[meer...]

30/04/10
Stallergenes’ websites get a brand new look!

[meer...]

19/04/10
Positive results for Oralair® phase III trial in the USA

[meer...]

22/03/10
Informatie voor artsen en apothekers over de beschikbaarheid en vergoeding van Staloral producten per maart 2010

[meer...]

22/03/10
2009 Financial results

[meer...]

10/12/09
Very positive 3-year results of the long-term study

[meer...]

27/11/09
Stallergenes is granted a marketing authorization for Oralair in Europe

[meer...]

07/10/09
Informatie voor artsen en apothekers over niet-geregistreerde allergeenproducten per 1 oktober 2009

[meer...]

22/09/09
Immunotherapy tablet containing recombinant allergen of birch pollen: positive results for a phase IIb/III trial

[meer...]

22/09/09
Geaccrediteerd: 2nd State of the art Symposium on allergen specific immunotherapy

[meer...]

27/08/09
A brand name for the 2nd sublingual desensitization tablet produced by Stallergenes

[meer...]

29/06/09
Nieuws omtrent vergoeding Staloral

[meer...]

23/06/09
XVIII Congress of the European Academy of Allergy and Clinical Immunology (EAACI)

[meer...]

10/06/09
Ook onze nieuwsbrief ontvangen?

[meer...]

13/05/09
Nieuwsbrief 1

[meer...]

04/05/09
House dust mites desensitization tablets: Positive results from a phase IIb/III clinical trial

[meer...]

20/01/09
Oralair® Grasses obtains a pediatric Market Authorisation in Germany

[meer...]

03/12/08
Recombinant berkenpollen vaccin veilig en effectief bij patiënten met rhinoconjunctivitis ten gevolge van allergie voor berkenpollen

[meer...]

24/11/08
Launch of a ph.III clinical trial in adults for Oralair Grasses in the US

[meer...]

10/09/08
Stallergenes inaugurates the biggest pharmaceutical allergen production unit in the world

[meer...]

27/08/08
Oralair® Grasses 300 IR : Highly positive clinical results in a pharmacodynamic study conducted in an allergen challenge chamber

[meer...]

24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses

[meer...]